Ander Estella‐Hermoso de Mendoza

Author

Also Known As

A Estella-Hermoso de Mendoza, A. Estella-Hermoso de Mendoza, A. Mendoza, Ander Estella-Hermoso de Mendoza, Ander Estella‐Hermoso de Mendoza, Ander Mendoza

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Universidad de Navarra Centro de Investigación del Cáncer Universidad de Salamanca Clinica Universidad de Navarra WuXi AppTec (China)

About

Ander Estella‐Hermoso de Mendoza is an author at Universidad de Navarra specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	733
2	Engineering	5	5	223
3	Biochemistry	3	3	137
4	Natural Sciences	1	1	85
5	Biomedical Engineering	1	1	110

Ander Estella‐Hermoso de Mendoza

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies Edurne San José‐Eneriz, Xabier Agirre, Obdulia Rabal, Nature Communications Hematological MalignancyReversible Chemical ProbesEpigenetic DrugsNovel TherapyChemical Series	2017	161
Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease Carmen Roncal, E. Martínez-Aguilar, Josune Orbe, Scientific Reports	2019	154
Lipid raft-targeted therapy in multiple myeloma Faustino Mollinedo, Janis de la Iglesia-Vicente, Consuelo Gajate, Oncogene Hematological MalignancyLipid Raft-targeted TherapyMedicineImmunologyImmune Checkpoint Inhibitor	2010	121
In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma Ander Estella‐Hermoso de Mendoza, Véronique Préat, Faustino Mollinedo, Journal of Controlled Release NanoparticlesNeuro-oncologyNanomedicineEngineeringGlioma	2011	110
GPR55: A therapeutic target for Parkinson's disease? Marta Celorrio, Estefanía Rojo-Bustamante, Diana Fernández‐Suárez, Neuropharmacology Functional SelectivityMedicineNeurochemical BiomarkersNeurologyPharmacology	2017	102
<i>In vitro</i> and <i>In vivo</i> Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts Faustino Mollinedo, Janis de la Iglesia-Vicente, Consuelo Gajate, Clinical Cancer Research	2010	90
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, Journal of Medicinal Chemistry Hdac InhibitorsDrug TargetNeurochemical BiomarkersAlzheimer ’Pharmaceutical Chemistry	2016	85
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, European Journal of Medicinal Chemistry Dual Phosphodiesterase 5Medicinal ChemistryNeurodegenerative DiseasesAlzheimer's DiseaseMedicine	2018	67
Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization Ander Estella‐Hermoso de Mendoza, Marta Rayo, Faustino Mollinedo, European Journal of Pharmaceutics and Biopharmaceutics Lipid PreparationVitro CharacterizationEngineeringLipid NanoparticlesMicro-encapsulation	2007	55
Antitumor Alkyl Ether Lipid Edelfosine: Tissue Distribution and Pharmacokinetic Behavior in Healthy and Tumor-Bearing Immunosuppressed Mice Ander Estella‐Hermoso de Mendoza, Miguel Ángel Campanero, Janis de la Iglesia-Vicente, Clinical Cancer Research	2009	48

Page 1